A new drug called Opana, known as oxymorphone, has recently
been released by the FDA available as a pain medication by prescription.
Like other effective centrally-acting
analgesics, some of the additional effects of oxymorphone can include euphoria, anxiolysis, promotion of sociability, and
other similar effects that can cause psychological addiction to the drug. Also, like all other opiates, oxymorphone is physically
addictive and can cause opiate withdrawal symptoms.
However in cases where real physical pain is present, almost invariably
the body prevents the development of true addiction to oxymorphone for a combination of psychological, neurological, and endocrinological
On the other hand oxymorphone can generate a serious narcotic habit rather quickly in those who take it recreationally
in that it has powerful euphorigenic properties which some rank as the highest amongst narcotics, many placing it above morphine,
heroin, hydromorphone, and dextromoramide.
The significant antidepressant properties of oxymorphone and other
dihydromorphinone class semi-synthetic opioids is currently of interest to both the underground and the medical establishment,
the latter of whom are "re-discovering" the anti-depressant effect and its relatively low ratio of toxic effects
and lack of association with patient suicide attempts and Opana ER has been proposed as an alternative to methadone
and other extended-release and/or long lasting drugs like MS Contin, extended-release dihydrocodeine, buprenorphine, and 24-hour
hydromorphone tablets for opioid detoxification and maintenance.
Endo withdrew the original Numorphan tablets from
the market in 1972 as the result of regulatory and market pressures and other considerations as it was passionately sought,
by any means necessary, by some narcotics addicts. Until its removal from the United States market at that point, oxymorphone
in the form of Numorphan 10 mg instant-release tablets was one of the most sought-after and well-regarded opioids of the IV
drug using community. Because of its low bioavailability, 10% when taken orally, a 10mg tablet represents 10 times the average
IV dose in a single tablet. Known popularly as "blues" or "Nu- Blues" for their light blue color, the
tablets contained very few insoluble bindersmaking them easy to injectand were extremely potent when used intravenously. "Blues"
were also considered to be especially euphoric; comparable to or better than heroin.
Slang terms for oxymorphone
include: blues, biscuits, blue heaven, new blues (although the immediate-release tablets are pink and off-white), octagons
(extended release), [strength] octagons, stop signs, pink, pink heaven, biscuits (could also be Dilaudid tablets, meprobamate
tablets, or formerly Quaaludes, pink heaven, pink lady, Mrs O, Orgasna IR, OM, Pink O, The O Bomb (by analogy to the slang
term for hydromorphone "H Bomb") and others.
Oxymorphone is not a component of "T's and blues",
1970s slang for a combination of pentazocine ("T's") and pyribenzamine ("blues").
Nor are "blues" 10 mg Valium tablets, which are known as Blue Bombers and BBs.
Oxymorphone was available in
the United States only as suppositories and ampoules for hospital use for 35 years until recently, making diversion of the
ampoules and the time-consuming proceess of melting, mixing with water, then chilling the suppositories and drawing off the
aqueous portion of the results and boiling down as the major means of use of oxymorphone pharmaceuticals in means inconsistent
with their labelling in the USA. Rare cases of users baking their own at home by extracting oxycodone from pharmaceuticals
and converting it to oxymorphone have been reported in the a number of countries. In some cases, codeine is the starting material
with morphine, or more rarely thebaine, being the intermediate. In those cases, the more common end products sought are morphine
salts, morphine base, heroin, dihydromorphine, desomorphine, and hydromorphone.
OPANA tablets may be abused by
crushing, chewing, snorting or injecting the product. These practices pose a significant risk to the abuser that could result
in overdose and death .
In common with other opioids, oxymorphone overdosage is characterized by respiratory
depression, extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes
bradycardia and hypotension. In a severe case of overdose, apnea, cirulatory collapse, cardiac arrest, and death may